ARK Investment Management LLC Has $15.93 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

ARK Investment Management LLC cut its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Free Report) by 4.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 15,151 shares of the biopharmaceutical company's stock after selling 714 shares during the quarter. ARK Investment Management LLC's holdings in Regeneron Pharmaceuticals were worth $15,928,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. Norden Group LLC boosted its holdings in Regeneron Pharmaceuticals by 48.1% in the 1st quarter. Norden Group LLC now owns 388 shares of the biopharmaceutical company's stock valued at $373,000 after purchasing an additional 126 shares during the last quarter. Quent Capital LLC boosted its holdings in Regeneron Pharmaceuticals by 5.1% in the 1st quarter. Quent Capital LLC now owns 390 shares of the biopharmaceutical company's stock valued at $375,000 after purchasing an additional 19 shares during the last quarter. Csenge Advisory Group lifted its holdings in shares of Regeneron Pharmaceuticals by 12.3% in the 1st quarter. Csenge Advisory Group now owns 449 shares of the biopharmaceutical company's stock worth $432,000 after acquiring an additional 49 shares during the last quarter. Envestnet Portfolio Solutions Inc. lifted its holdings in shares of Regeneron Pharmaceuticals by 33.7% in the 1st quarter. Envestnet Portfolio Solutions Inc. now owns 1,588 shares of the biopharmaceutical company's stock worth $1,528,000 after acquiring an additional 400 shares during the last quarter. Finally, Empowered Funds LLC lifted its holdings in shares of Regeneron Pharmaceuticals by 34.5% in the 1st quarter. Empowered Funds LLC now owns 1,353 shares of the biopharmaceutical company's stock worth $1,302,000 after acquiring an additional 347 shares during the last quarter. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Regeneron Pharmaceuticals Price Performance

Shares of REGN stock traded up $3.94 during mid-day trading on Friday, reaching $828.42. The stock had a trading volume of 563,554 shares, compared to its average volume of 522,278. Regeneron Pharmaceuticals, Inc. has a 12-month low of $783.57 and a 12-month high of $1,211.20. The company has a market cap of $91.04 billion, a P/E ratio of 20.50, a price-to-earnings-growth ratio of 3.12 and a beta of 0.15. The business has a 50-day simple moving average of $1,021.70 and a 200 day simple moving average of $1,036.38. The company has a current ratio of 5.28, a quick ratio of 4.46 and a debt-to-equity ratio of 0.09.

Insider Activity at Regeneron Pharmaceuticals

In other news, CFO Christopher R. Fenimore sold 5,680 shares of the business's stock in a transaction that occurred on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total value of $6,846,274.40. Following the completion of the sale, the chief financial officer now directly owns 15,305 shares in the company, valued at approximately $18,447,575.65. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 7.48% of the company's stock.

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Evercore ISI decreased their price objective on shares of Regeneron Pharmaceuticals from $1,250.00 to $1,175.00 and set an "outperform" rating on the stock in a report on Thursday, October 24th. StockNews.com lowered shares of Regeneron Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Monday. Cantor Fitzgerald restated a "neutral" rating and issued a $1,015.00 price objective on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Royal Bank of Canada decreased their price target on shares of Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an "outperform" rating for the company in a research report on Friday, November 1st. Finally, Piper Sandler cut their target price on shares of Regeneron Pharmaceuticals from $1,242.00 to $1,195.00 and set an "overweight" rating on the stock in a research note on Friday, November 1st. One equities research analyst has rated the stock with a sell rating, four have issued a hold rating and eighteen have given a buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of "Moderate Buy" and an average price target of $1,092.62.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.